KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $399.9 million.

  • Alnylam Pharmaceuticals' Change in Receivables rose 97803.03% to $399.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $603.7 million, marking a year-over-year increase of 250526.47%. This contributed to the annual value of $86.6 million for FY2024, which is 157.95% down from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Change in Receivables is $399.9 million, which was up 97803.03% from $136.9 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Receivables peaked at $399.9 million during Q3 2025, and registered a low of -$39.7 million during Q1 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Change in Receivables averaged around $45.6 million, with its median value being $10.7 million (2021).
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Receivables crashed by 47067.89% in 2022 and then soared by 191317.07% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Change in Receivables (Quarter) stood at $59.4 million in 2021, then fell by 10.4% to $53.3 million in 2022, then tumbled by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then soared by 571.95% to $399.9 million in 2025.
  • Its Change in Receivables was $399.9 million in Q3 2025, compared to $136.9 million in Q2 2025 and $7.4 million in Q1 2025.